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A B S T R A C T
Ageing comes with an increased propensity in the alteration of human organ and body functions, which
can e.g. result in multi-morbidity, frailty, polypharmacy, altered medication safety and/or efﬁcacy, and
problems with the practical use of medicines in a real world setting. Such problems may e.g. involve
difﬁculties opening containers, swallowing large tablets, breaking tablets by hand, or correctly
understanding the user instruction. This review aims to summarize the European regulatory activities
towards better medicines for older people, with a main focus on formulation development and the
overall drug product design. It addresses the ICH E7 guideline “Studies in support of special populations,
geriatrics”, the ICH Q8 guideline “Pharmaceutical development”, the EMA good practice guide on “Risk
minimisation and prevention of medication errors” and the forthcoming EMA CHMP QWP reﬂection
paper on the “Quality aspects (pharmaceutical development) of medicines for older people”. In addition,
three key aspects to the practical use of medicines by older people are discussed in a wider context:
multi-particulates including small tablets (also referred to as mini-tablets), ease of opening and storage
conditions. Furthermore, attention is paid to work in progress e.g. incentives by the European national
drug regulatory authorities, and patient centric drug product development.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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According to Eurostat, the proportion of older people in the
European Union (EU) i.e. people aged 65 years or over, is expected
to increase from 17% in 2008 to 30% in 2050 (EMA, 2016a). The
increase results from a variety of measures, e.g. reduction in under-
ﬁve mortality, a healthy environment, adequate health care
systems and timely access to safe and effective medicines from
birth into old age (Sadana et al., 2016; Worku and Woldesenbet,
2015). As ageing comes with gradually altering human organ and
body functions, older people may differ from adults of younger or* Corresponding author.
E-mail address: da.v.riet@cbg-meb.nl (D.A. van Riet-Nales).
1 Retired.
http://dx.doi.org/10.1016/j.ijpharm.2016.05.001
0378-5173/ã 2016 The Authors. Published by Elsevier B.V. This is an open access article unmiddle age in many ways. Common differences e.g. relate to
limited visibility, hearing, swallowability, motor functions, hand-
eye coordination, health literacy; increased susceptibility to
diseases and risk for multiple medication use and polypharmacy;
altered medication absorption, distribution, metabolism and
elimination; difﬁculties with self-caring or frailty. Older people
will also commonly be living alone or with a person who is just as
old, meaning any possible assistance may be limited (Stegemann
et al., 2010). Thus, it is essential that the special needs of older
people are taken into consideration during the development,
approval and use of medicines (EMA, 2016a). This review aims to
summarize the European regulatory activities towards better
medicines for older people, with a main focus on formulation
development and the overall drug product design.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In 1994, the International Conference on Harmonisation (ICH)
efﬁcacy guideline “Studies in support of special populations:
geriatrics” (E7) was adopted to address the expected increase in
the proportion of older people in the ICH regions of that time (USA,
Europa, Japan) as well as the impact of ageing on the human organ
and body functions. The guideline concludes that the “use of drugs
in this population requires special consideration due to the frequent
occurrence of underlying diseases, concomitant drug therapy and the
consequent risk of drug interaction”. Therefore, it stipulates that
“patients entering the clinical trials should be reasonably representa-
tive of the population that will be later treated with the drug” and that
“it is also important not to exclude unnecessarily patients with
concomitant illnesses” (ICH, 1994). As a consequence, the guideline
requires companies to include a representative number of older
people in the phase 2 and 3 clinical trials (ICH, 1994; EMA CHMP,
2010).
The E7 guideline acknowledges the potential impact of the drug
product formulation on older people’s medication responsiveness
towards safety/tolerability and efﬁcacy (ICH, 1994). However, and
unlike the European regulation on “Medicinal products for
paediatric use” (2006), it does not speciﬁcally address the
suitability of the formulation for use by older people as such
(EU, 2006). For this and other reasons, the subsequent ICH Q8
guideline on “Pharmaceutical development” (2005) stipulates that
“the product should be designed to meet patients’ needs and the
intended product performance” and that “the Pharmaceutical
Development section (of the Marketing Authorisation dossier) should
describe the knowledge that establishes that the type of dosage form
selected and the formulation proposed are suitable for the intended
use” (ICH, 2005).
It is known that older people encounter a wide variety of
practical medication problems (Hennessy et al., 2011; Kairuz et al.,
2008; Mehuys et al., 2012; Notenboom et al., 2014; van Geffen
et al., 2010). As a consequence, health care professionals may be
left with no other choice than dispensing off-label medicines, or
recommending off-label instructions to authorised drug products
(Jackson et al., 2012; Kwint et al., 2013; Stegemann, 2015). Such
instructions may e.g. involve opening capsules and taking the
contents with food or drink to ease swallowing, or the
administration of a dispersion of crushed tablets through feeding
tubes in patients who are seriously ill or suffering from swallowing
difﬁculties (Cornish, 2005; Stegemann, 2015). In addition, it is
known that older people may develop their own strategies to
accommodate practical medication problems, such as removing
tablets from the primary package for storage in a multi-
compartment compliance aid to ease medication management,
or using tablet splitters as an alternative to breaking tablets by
hand (Elliott et al., 2016; Zedler et al., 2011). However, any off-label
administration strategy can alter the medicine’s safety and efﬁcacy
proﬁle through e.g. the risk for degradation, dosing inaccuracies or
altered bio-availability (Richey et al., 2012; Stegemann, 2015).
Despite the requirements of the E7 guideline, evidence
indicates that an unacceptably low proportion of older people
have been included in clinical trials for medicines that are not
unique to older age (Beers et al., 2014; Cherubini et al., 2010). This
implies that the real world practical medication problems that are
associated with older age may neither have been observed by
companies during the clinical trials nor by the regulatory bodies
during the marketing authorisation phase. While some stake-
holders have voiced the need for a Geriatric Regulation and
associated Geriatric Investigation Plan, the EMA considers that
older people are the main users of medicines and that their needs
are better addressed by integrating the assessment of medicines
for use by older people in the general framework, and to addadditional targeted guidance where needed (Cerreta et al., 2012;
De Spiegeleer et al., 2016). In order to better ensure the inclusion of
older people in clinical trials, article 6 of the recent regulation on
clinical trials stipulates that member states need to assess whether
“the groups of subjects participating in the clinical trial represent the
population to be treated” (European Commission (EC), 2014).
3. EMA geriatric expert group
The EMA is responsible for the centralised evaluation of new
medicines and associated generics, post approval drug monitoring
(pharmacovigilance), and guideline development (Enzmann and
Schneider, 2008). In addition, the 28 EU member states (and over
28 drug regulatory authorities) are responsible for the evaluation
of innovative and generic medicines through the national, mutual
recognition and decentralized procedures and for providing
experts to the EMA scientiﬁc committees and working parties.
Moreover, most of the EMA committee members are relying on the
support of the national drug regulatory authorities for the
assessment of the clinical, pre-clinical and quality data (Bachmann,
2008).
In 2011, the EMA has published a Geriatric Medicines Strategy to
better address the needs of older people within the existing
legislative framework. The aim of the strategy is ﬁrstly to ensure
that the medicines that are used by older people are of “high
quality, and appropriately researched and evaluated, throughout the
lifecycle of the product, for use in this population”; and secondly,
“improving the availability of information on the use of medicines for
older people, and thereby helping informed prescription”. The EMA
considers that both aims can be realized by a range of measures
including the establishment of a Geriatric Expert Group (GEG) to
provide scientiﬁc advice to the EMA Committee for Medicinal
Products for Human use (CHMP) and the EMA secretariat; the
development of (clinical) guidelines speciﬁc to older people; the
inclusion of considerations on older people in other EMA docu-
ments where appropriate; the development of a dedicated EMA
webpage; and the organisation of workshops (Cerreta et al., 2012;
EMA, 2011).
As part of the EMA Geriatric Medicines Strategy, the CHMP has
published a draft “Points to consider on frailty: evaluation
instruments for baseline characterisation of clinical trials popula-
tion” (EMA CHMP, 2016). Also, the Pharmacovigilance Risk
Assessment Committee (PRAC) has issued a Good Practice Guide
on “Risk minimisation and prevention of medication errors”
including a chapter dedicated to elderly patients (EMA PRAC,
2015a). Furthermore, the EMA CHMP Quality Working Party (QWP)
is developing a reﬂection paper on the “Quality aspects (pharma-
ceutical development) of medicines for older people” (EMA CHMP,
2013). The paper is intended to be read in conjunction with the
existing regulatory provisions, including any other EMA document,
the EU Commission guidelines and the European pharmacopoeia
(Ph. Eur.) (EMA, 2016b).
Many of the current QWP guidelines, reﬂection papers and
Question and Answers documents (Q&As) contain statements on
the practical use of medicines in a real world setting. Most of these
statements are related to patients of any age, yet many are
particularly important to older people (EMA, 2016b). As state-
ments that have already been published elsewhere are not
intended to be repeated in QWP reﬂection papers, it is crucial
that companies are familiar with all QWP documents. For example,
the guideline on the “Quality of transdermal patches” (2014)
indicates that “the suitability of the transdermal patch in use should
be fully discussed” and that the aspects to be considered e.g. include
“the identiﬁcation, markings, appearance and visibility of the
transdermal patch”; the “site of administration, and change in site
per dose”; and “avoidance of cutting of the transdermal patches”.
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likely to self-administer patches correctly, and that they are able to
control if a patch is still on their skin, accidentally attached to
another person (child), or adequately removed (EMA CHMP, 2014;
EMA PRAC, 2015a,b).
4. Medication errors
Medication errors can be deﬁned as “any unintended failure in
the drug treatment process that leads to, or has the potential to lead to,
harm to the patient” (EMA PRAC, 2015a,b). It is important to realize
that such unintended failures may be due to both intentional as
well as unintentional deviations from the instructions in the
authorised product information i.e. in the product label, package
leaﬂet or summary of product characteristics (SmPC) (Kwint et al.,
2013; Stegemann, 2015; Urban et al., 2016). Medication errors can
occur in patients of any age and at any stage of pharmacotherapyFig. 1. Examples from the EMA Good Practice Guide on “Risk minimisation and preventio
design of medicines for use by older people.e.g. prescriptions by health care professionals; dispensing by
community and hospital pharmacies; storage at pharmacies,
wards, patient homes, holidays; preparing the product for
administration; and the actual administration to or intake by
the patient (EMA PRAC, 2015a).
As older people are the main users of medicines and have
speciﬁc needs, they are particularly prone to medication errors
(Elliott et al., 2016; EMA PRAC, 2015a; Urban et al., 2016).
Medication errors place a high burden on health care resources.
For example, Leendertse et al. showed that the main determinants
for preventable medication related hospital admissions included
impaired cognition, the living situation and polypharmacy. The
author also estimated that the medical costs in older people was
s5637 per submission (Leendertse et al., 2011). The study did not
evaluate which proportion of the admissions was due to a
suboptimal drug product design for patients of older age, or due
to the fact that medicines had been swapped as a result ofn of medication errors” which are considered to be of relevance to the drug product
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underpins the need for further research into the cost or savings on
national health budgets as well as improved patient health aspects
by reimbursing potentially more expensive drug products that well
address older people’s needs, rather than those cheap(est) in class
only.
The EMA Good Practice Guide on “Risk minimisation and
prevention of medication errors” addresses the need to improve
the current situation (EMA PRAC, 2015a). The Guide is intended to
be read in conjunction with the addendum on “Risk minimization
strategy for high-strength and ﬁxed-combination insulin prod-
ucts” and another Good Practice Guide on “Recording, coding,
reporting and assessment of medication errors” (EMA PRAC, 2015b,
c). The Guide relates to medicines for people of any age, however,
many aspects are of particular importance to older people. Annex 1
“Potential sources of medication error in medicinal product
design” lists possible causes of medication errors. In Annex 2
“Design features which may reduce the risk of medication errors”
possible risk mitigation measures are proposed (EMA PRAC,
2015a). However, there is no direct link to the issues identiﬁed
in Annex 1 and Annex 2 (Fig. 1).
As the Guide is written from a pharmacovigilance perspective,
it takes a retrospective view on measures in the pharmaceutical
design of medicines to mitigate medication errors i.e. from real
world problems to the proposed design features. We consider that
a prospective strategy during pharmaceutical drug development
and at the time of marketing authorisation may further add to
mitigating risk. Existing, future revisions of, and new regulatory
(quality) documents may serve this goal.
For products that are already on the market, pharmaceutical
companies should take account of the provisions of Directive
2001/83 article 23. This article states that “After a marketing
authorisation has been granted, the marketing authorisation holder
shall, in respect of the methods of manufacture and control provided
for in Article 8(3)(d) and (h), take account of scientiﬁc and technical
progress and introduce any changes that may be required to enable
the medicinal product to be manufactured and checked by means of
generally accepted scientiﬁc methods” (EU, 2001). However, it is not
yet clear if, and if so, when, drug regulatory authorities can
require companies to update the quality of drug products with
reference to this obligation. For example, if and when companies
can be asked to add information to the package leaﬂet on tablet
chewing or crushing; and when tablets cannot be chewed or
crushed, if and when, companies can be asked to reduce the size
of large tablets and/or to develop an additional easy to swallow
formulation.
5. Reﬂections for older people: learning lessons from
paediatrics
According to the “Procedure for European Union guidelines and
related documents within the pharmaceutical legislative frame-
work”, the reﬂection paper on the “Quality aspects (pharmaceuti-
cal development) of medicines for older people” is intended to
communicate the current status of discussion and to invite
comments on the topics addressed. Using this approach, reﬂection
papers can contribute to the future development of CHMP or ICH
guidelines, which are then intended to reﬂect the current status of
scientiﬁc and technical progress, and to be considered as “soft law”
with a quasi-binding character (EMA, 2009). As the earlier
“Reﬂection paper on formulations of choice for the paediatric
population” was commonly used as if it would provide binding
information, it is important that the reﬂection paper for older
people will clearly note how its reﬂections are to be understood
(EMA CHMP, 2005).As with the drafting of the “Guideline on the pharmaceutical
development of medicines for paediatric use”, the development of
the reﬂection paper on “Quality aspects (pharmaceutical develop-
ment) of medicines for older people” infers that a three pillar
approach will be followed (EMA CHMP and PDCO, 2013; EMA
CHMP, 2013). The development of the reﬂection paper is therefore
intended to start with an analysis of the relevant scientiﬁc
literature and post-marketing data (Messina et al., 2015). Also a
close interaction with stakeholders on practical issues is foreseen
as well as a gap analysis of how marketed authorisations are not
fully meeting the needs of older people (EMA CHMP, 2013;
Notenboom et al., 2014). This information can then also be used by
all stakeholders (academia, industry, regulatory authorities) to
focus their research on the areas of most interest to healthy ageing.
Where appropriate, it is envisaged that the quality reﬂections for
older people will follow a similar thought process as the guidance
already adopted for paediatrics.
According to the aforementioned paediatric guideline, a
(paediatric) medicine/(paediatric) medicinal product can be
deﬁned as “a (paediatric) formulation in a particular strength
(e.g. tablets 5 mg, solution for injections 5 mg/ml) and, in case of
(paediatric) formulations for single use, the labelled container
contents (e.g. solution for injection 5 mg/ml, 1 ml = 5 mg or
2 ml = 10 mg)”, where a (paediatric) formulation is to be under-
stood as “the composition (and not stated, but also meant, the
appearance) of a particular dosage form of a medicine for
(paediatric) use” (EMA CHMP and PDCO, 2013). This implies that
companies may need to develop a range of drug products, i.e.,
different types of dosage forms and/or formulations and/or
strengths and/or container closure systems and/or measuring
and administration devices, to address the variety of special needs
across the overall target patient population of a medicine.
When deciding on the portfolio of drug products in which a
medicine will be put on the market, besides manufacturability and
ﬁnancial considerations, it is expected that companies also
consider the possibility of an increased risk for medication errors
due to patient confusion, e.g. when patients do not recognize that
drug products that are prescribed by different health care
professionals actually represent the same medicine. Thus, compa-
nies need to consider a “patient centric approach” whereby a
speciﬁc design approach is intended to address a variety of needs
across the target population rather than a gold standard approach
for each problem and each subset speciﬁcally (Hanning et al., 2016;
Sharma, 2015; Stegemann, 2016).
Although the term patient centric medicines is increasingly
employed in scientiﬁc publications and an American Association of
Pharmaceutical Scientists’ (AAPS) focus group on patient centricity
has been installed, a harmonized deﬁnition in the context of
pharmaceutical product design is not yet available (AAPS, 2016;
Stegemann, 2016). For the time being, the authors consider that
patient centric medicines can be deﬁned as those “that have been
designed to address the variety of needs of individual patients,
caregivers and health care professionals in a real world setting and
across the target patient population”. This deﬁnition is consistent
with Hanning et al. indicating that a patient centric formulation
development refers to “considering the end user from the
beginning of the formulation process and right through the
development to an end product”, and Zucca et al. indicating that
“the ﬁrst step in ensuring patient-centred quality of care is to ask
the patient about the care they would like” (Hanning et al., 2016;
Zucca et al., 2016).
In the next paragraphs, some speciﬁc aspects relevant to the
pharmaceutical development of medicines for older people will be
discussed in a wider context.
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Oral liquid formulations are known for a range of potential
problems such as bad taste, need for storage in the refrigerator,
limited stability, difﬁcult portability and/or errors when measuring
the dose. Oral ﬂexible solid dosage forms (multi-particulates) have
been proposed as a valuable alternative. In the past, multi-
particulate formulations mainly included powders and granules.
However, small sized tablets (also referred to as mini-tablets in the
scientiﬁc literature) are increasingly being accepted as an oral solid
ﬂexible paediatric dosage form (van Riet-Nales et al., 2016).
Currently, a harmonized deﬁnition on the size of small (mini-)
tablets is not available. In the draft version of the aforementioned
paediatric guideline, they were considered as tablets up to 5 mm
diameter (EMA CHMP, 2011). However, the categorization of
tablets into small, medium, large and very large size was not
supported by stakeholders during the public consultation as the
scientiﬁc data was scarce and fragmented. Thus the deﬁnition of
small (mini-)tablets is open for discussion.
Evidence suggests that the acceptability (including the risk of
choking) of mini-tablets in young children relates to tablet size,
shape, coating, palatability, and the time necessary to dissolve in
the mouth (Liu et al., 2014). If sufﬁciently small (2-mm) and rapidly
dissolving, they may be used from pre-term birth (Klingmann et al.,
2016). In older people, the patient acceptability of mini-tablets that
are to be taken on their own has hardly been investigated
(Hayakawa et al., 2016; Liu et al., 2016). Nevertheless, mini-tablets
may already be well known to older people due to vitamin D
supplementation (Figs. 2 and 3).
We believe that the aspects to be considered in the suitability of
mini-tablets for older people may be similar, but also different to
children. Such differences may e.g. relate to the relationship
between tablet size, shape, coating, and, where appropriate, colour,
on e.g. sticking of tablets between the teeth, or sticking to theFig. 2. Polypharmacy in an older home-dwelling couple: challenges in medication upper and back parts of the mucosal cavity; picking up tablets from
the container and after dropping; visibility in and outside the
primary container, in multi-compartment compliance aids or in
multi-dose drug dispensing systems. In addition, the patient
acceptability, preference and usability of different types and sizes
of mini-tablets by older people in comparison with other types of
dosage forms generally used in older age remains to be
investigated. As we ﬁnd it difﬁcult to pick up 2-mm tablets by
hand ourselves, we believe that it is likely that 1-mm and 2-mm
mini-tablets would need to be administered to older people
through a medical device. The Swedish Medical Products Agency
(MPA) has already authorised 3-mm diameter tablets for use in
Parkinson patients by administration through a dedicated dose
dispenser (MPA (Läkemedelsverket), 2014).
7. Ease of opening
Older people may experience difﬁculties opening medication
packages, for example because of lack of hand grip and strength,
impaired hand-eye coordination, or because they were simply not
aware of the peel-off rather than push-through character of a
blister strip (Hennessy et al., 2011; Kairuz et al., 2008; Philbert
et al., 2014; van Geffen et al., 2010). As current regulatory
provisions do not foresee in testing the user friendliness of
commonly applied container closure systems, older people may
beneﬁt from further attention to this topic.
Since the European legislation does not include any obligation
to pack medicines in child-resistant containers, it is up to the legal
provisions of the European member states and/or the opinion of
the EMA or European drug regulatory authorities to decide if
medicines need to be packed in child-resistant containers, and if
so, when. For example, the UK Medicines & Healthcare products
Regulatory Agency (MHRA) requires that products containing
paracetamol, aspirin and more than 24 mg of elemental iron arerecognition and use of a small (mini-) tablet (vitamin D, davaron, left picture).
Fig. 3. Polypharmacy in an older home-dwelling couple. Medication of one of the patients two weeks later. The use of methyldopa is discontinued. The patient is given a
different trademark of atorvastatin tablets with a different product appearance.
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effervescent or in single dose units (MHRA, 2016). In addition, it is
known that other authorities have more implicit rules which are
based on the consideration that drug products must be packed in
child-resistant containers when the intake of a single unit may
bring serious harm to the child, e.g. oxycodone, methylphenidate
and apixaban. Others may rather consider that child-resistant
packages may bring little beneﬁt, as medicines must be kept out of
the reach and sight of children (Fig. 4). In any case, it must be
carefully assured that child-resistant containers can be adequately
opened by older people, for example by showing compliance to the
ISO standards for child-resistant closures (ISO 2016a; ISO 2016b).
8. Storage
Older people are likely to use more than a single medicine
concurrently (Figs. 2 and 3). The concept is commonly referred to
as multiple medication use or, in cases where more than 5 drug
products are used, polypharmacy (Mortazavi et al., 2016). Multiple
medication use and polypharmacy may necessitate the need to
take speciﬁc measures to ease medication management, improve
patient adherence and avoid the risk for medication errors. For
example, medicines may be stored by patients at a convenient
location (Fig. 4). As another example, they may be stored in multi-
dose drug dispensing packages or multi-compartment compliance
aids (Kwint et al., 2013; Mehuys et al., 2012; Sino et al., 2014)
(Fig. 5).
Multi-morbidity in older people also implies that they may be
regularly visiting different health care professionals and moving
from home to hospital, institutions and back again. However,
patients may be using different trademarks of the medicines in the
different settings. It is known that the interchangeability of drug
products containing the same active substance from different
companies requires particular attention in order to ensure
adequate clinical efﬁcacy, medication recognition and adherence
to potentially different user instructions (Seoane-Vazquez et al.,2016; Urban et al., 2016) (Fig. 3). It is also known that patients may
gather large quantities of medicines at home when they are
receiving new prescriptions upon each visit or transition of care.
This may result in e.g. accidental overdosing, the use of products
long after their (in-use) shelf-lives had expired, or environmental
waste.
9. Work in progress
As indicated, the EMA is paying increased attention to the
special needs of older people, including the drug product design
(EMA, 2016a,b; EMA CHMP, 2013; EMA PRAC, 2015a,b,c). At the
same time, it is known that national drug regulatory authorities
and the European Pharmacopoeia are developing additional
measures to support this aim. For example, the Medicines
Evaluation Board in the Netherlands (MEB) has adopted a strategic
business plan including a focus on the promotion of the good use of
medicines, patient directed assessments and innovation (MEB,
2013). It is expected that older people will highly beneﬁt from this
strategy. Also, in collaboration with the Expertisecentre Pharma-
cotherapy in Old persons (EPHOR), the MEB is collecting data on
older people that is less visible from the marketing authorisation
approval documents. Furthermore, the MPA has, in co-operation
with the National Board of Health and Welfare and other Swedish
health agencies, initiated a workplan to identify problems in
relation to the pharmaceutical treatment of older people in order
to propose improvement measures (MPA, 2016a). Also, the MPA
grants permissions for the dispensing of oral medications outside
their authorised package. In order to receive an opening
permission of the container closure system for automated dose
dispensing, the marketing authorisation holder has to perform
stability studies of the drug product in open storage. The
requirements of the scope of the studies depend on the conclusions
drawn from the stability data in the marketing authorisation
dossier. The studies should include an analysis of stability
indicating parameters such as degradation products (MPA, 2016b).
Fig. 4. Measures to ease medication management: home storage of medicines by an
older home-dwelling couple on polypharmacy posing risks if young children are
present in the dwelling.
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Medicines & Healthcare (EDQM) has published a proposal for
revision of the European Pharmacopoeial (Ph. Eur.) test on theFig. 5. Use of multi-compartment compliance aids by an older home-dwelling couple uniformity of mass of tablet fragments following breaking by hand
(EDQM, 2015). The proposed revision is subject to multiple
interpretations by stakeholders as some consider that any break-
mark would need to comply with the test, whilst others consider
that this is not the case. Thus, further clariﬁcation is awaited. In any
case, it must be recognized that the guideline on “Summary of
Product Characteristics” clearly indicates that break-marks may be
present for ease of swallowing only (EU, 2009).
For break-marks that are intended to ease swallowing, it is (yet)
not considered necessary that the break-mark complies with the
Ph. Eur. test, as it is suggested that dosing accuracy will not be
affected by taking several fragments as a single dose. However, it
can be questioned if the current regulatory approach is in the
interest of public health. First of all, it implies that there is no
control on any loss of mass in case tablets are broken to ease
swallowing. Also, there is no control as to whether breaking really
eases swallowing, especially in case of fragments largely differing
in mass (and thus size). Moreover, regulators are increasingly
recognizing that off-label breaking for dose reductions is a
common practice, and that restrictions to the use of break-marks
for ease of swallowing are either not known or not practical in a
real world setting. Thus, further discussion on the scope of the Ph.
Eur. test is warranted.
10. Conclusion
A variety of measures has been installed over the last decades
to address the speciﬁc needs of special patient populations,
including older people (ICH 1994; ICH, 2005). The 2011 Geriatric
Medicines Strategy will further assist addressing older people’s
needs within the existing legislative framework (EMA, 2011). The
forthcoming EMA reﬂection paper on the “Quality aspects
(pharmaceutical development) of medicines for older people”
is expected to summarize the current status of discussion and to
invite comments on the topics addressed (EMA CHMP, 2013). It is
anticipated that the paper will follow a similar thought process as
adopted for the “Guideline on the pharmaceutical development of
medicines for paediatric use” (EMA CHMP and PRAC, 2013).
Furthermore, it is envisaged that the identiﬁcation of knowledge
gaps will stimulate research by industry, academia and/or
regulatory authorities into the domains where knowledge is still
scarce and fragmented (Gispen-de Wied and Leufkens, 2013). In
order to address older people needs, it must be acknowledged
that any practical problems currently experienced, are related to
products already on the market. Therefore, both a prospective as
well as retrospective approach to adequate (patient centric)
product design is warranted to better address older people’s
needs. A stakeholder discussion on the minimum quality stand-
ards to be met by any marketed product i.e. across the products
lifecycle from early market introduction, through variations and
end of sales, might be helpful.to ease medication management and ensure adequate drug adherence for a week.
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